U.S. Markets open in 7 hrs 45 mins

InMed Pharmaceuticals Inc. (IN.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
6.37+1.16 (+22.26%)
At close: 3:59PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.21
Open5.26
Bid6.36 x N/A
Ask6.40 x N/A
Day's Range5.26 - 6.39
52 Week Range4.70 - 14.85
Volume23,685
Avg. Volume9,278
Market Cap33.256M
Beta (5Y Monthly)2.57
PE Ratio (TTM)N/A
EPS (TTM)-2.65
Earnings DateMay 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.85
  • Will InMed Pharmaceuticals (TSE:IN) Spend Its Cash Wisely?
    Simply Wall St.

    Will InMed Pharmaceuticals (TSE:IN) Spend Its Cash Wisely?

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755
    PR Newswire

    InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755

    InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that dosing of subjects has begun in its second Phase 1 clinical trial with INM-755 ("755-102-HV"). INM-755 is being developed as a topical CBN-based cream to potentially treat Epidermolysis Bullosa ("EB") as well as potentially other dermatological diseases.

  • InMed Announces Completion of Share Consolidation
    PR Newswire

    InMed Announces Completion of Share Consolidation

    InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN) (OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), is pleased to announce, further to its press release dated June 19th, 2020, that in conjunction with its application to list its common shares on the Nasdaq Stock Market ("Nasdaq"), the Company has completed the consolidation of its issued and outstanding common shares on the basis of thirty-three (33) pre-consolidation common shares for one (1) post-consolidation common share (the "Consolidation").